Compare
EyePoint, Inc. vs Rapid Micro Biosystems, Inc. vs Bionano Genomics, Inc. vs Precipio, Inc.
| Latest fiscal year | EyePoint, Inc. EYPT | Rapid Micro Biosystems, Inc. RPID | Bionano Genomics, Inc. BNGO | Precipio, Inc. PRPO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $31.37M | $33.59M | $28.51M | $24.05M |
| Revenue growth (YoY) | -27.5% | +19.7% | -7.4% | +29.8% |
| Gross margin | n/a | n/a | 46.3% (computed) | 44.5% |
| Operating margin | -776.0% | -141.1% | -116.9% | -5.0% |
| Net margin | -739.4% | -140.3% | -92.6% | -1.5% |
| Net income | -$231.96M | -$47.12M | -$26.39M | -$363.0K |
| EPS (Diluted) | -$3.17 | -$1.05 | -$4.85 | -$0.23 |
| Operating cash flow | -$240.11M | -$31.06M | -$16.34M | $685.0K |
| Free cash flow | -$243.39M | -$31.91M | n/a | $359.0K |
| Cash & equivalents | $101.82M | $20.03M | $2.99M | $2.65M |
| Total assets | $364.00M | $74.85M | $73.58M | $21.32M |
| Total liabilities | $57.88M | $41.65M | $29.16M | $6.76M |
| Shareholders' equity | $306.11M | $33.21M | $44.42M | $14.56M |
| Return on year-end equity | -75.8% | -141.9% | -59.4% | -2.5% |
| Shares outstanding | 82.83M | n/a | 10.74M | 1.78M |
Revenue, most recent five fiscal years
| Fiscal year | EyePoint, Inc. | Rapid Micro Biosystems, Inc. | Bionano Genomics, Inc. | Precipio, Inc. |
|---|---|---|---|---|
| Latest | $31.37M Ended 2025-12-31 | $33.59M Ended 2025-12-31 | $28.51M Ended 2025-12-31 | $24.05M Ended 2025-12-31 |
| 1 year earlier | $43.27M Ended 2024-12-31 | $28.05M Ended 2024-12-31 | $30.78M Ended 2024-12-31 | $18.53M Ended 2024-12-31 |
| 2 years earlier | $46.02M Ended 2023-12-31 | $22.52M Ended 2023-12-31 | $36.12M Ended 2023-12-31 | $15.20M Ended 2023-12-31 |
| 3 years earlier | $41.40M Ended 2022-12-31 | $17.13M Ended 2022-12-31 | $27.80M Ended 2022-12-31 | $9.41M Ended 2022-12-31 |
| 4 years earlier | $36.94M Ended 2021-12-31 | $23.23M Ended 2021-12-31 | $17.98M Ended 2021-12-31 | $8.85M Ended 2021-12-31 |